J&J's Caplyta meets main goal of bipolar mania study

Johnson & Johnson said its late-stage trial of Caplyta for bipolar mania met its primary endpoint, advancing the experimental indication toward a potential label expansion. Caplyta is already approved for other uses, and success in bipolar mania could broaden its commercial opportunity, subject to regulatory review.